Skip to main content
Clinical Trials/NCT03655054
NCT03655054
Completed
N/A

SUBCUTANEOUS TIBIAL NERVE STIMULATION FOR URGENCY URINARY INCONTINENCE: A FOLLOW-ON STUDY

Valencia Technologies Corporation7 sites in 2 countries23 target enrollmentMarch 13, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Overactive Bladder
Sponsor
Valencia Technologies Corporation
Enrollment
23
Locations
7
Primary Endpoint
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as defined by the American Urological Association (30). The follow-on study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient-reported outcomes through 24 weeks of eCoinTM therapy (which is the same as 28 weeks from study device reimplantation).

Registry
clinicaltrials.gov
Start Date
March 13, 2019
End Date
September 12, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Individual participated in the eCoin Feasibility Study for Urgency Urinary Incontinence.
  • Individual was implanted with the study device during the eCoin Feasibility Study for Urgency Urinary Incontinence.

Exclusion Criteria

  • In the opinion of the investigator, individual is not a good candidate for participation in the study.

Outcomes

Primary Outcomes

Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

Time Frame: 12 weeks after device activation.

Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation.

Time Frame: 16 weeks after device implantation.

Instances of a related adverse event.

Secondary Outcomes

  • Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation.(28 weeks after device implantation.)
  • Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.(24 weeks after device activation.)

Study Sites (7)

Loading locations...

Similar Trials